VX-809 (Lumacaftor)
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
Discription | VX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF). | ||
---|---|---|---|
Targets |
|
Catalog Num | A10986 |
---|---|
Formula | C24H18F2N2O5 |
Molecular Weight | 452.4 |
CAS Number | 936727-05-8 |
SMILES | CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O |
Synonyms | VX809 |
Storage | Store lyophilized at -20ºC, keep desiccated. |
In vitro (25°C) | DMSO | 88 mg/mL (194.51 mM) | |
Water | Insoluble | ||
Ethanol | 6 mg/mL (13.26 mM) | ||
In vivo | 30% PEG400+0.5% Tween80+5% propylene glycol | 28 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 22.1 mL | 110.52 mL | 221.04 mL |
0.5 mM | 4.42 mL | 22.1 mL | 44.21 mL |
1 mM | 2.21 mL | 11.05 mL | 22.1 mL |
5 mM | 0.44 mL | 2.21 mL | 4.42 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2